## BRCA1 and its toolbox for the maintenance of genome is

Nature Reviews Molecular Cell Biology

11, 138-148

DOI: 10.1038/nrm2831

Citation Report

#	Article	IF	CITATIONS
1	Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Pakistan Journal of Medical Sciences, 1969, 30, 488-92.	0.3	13
2	Assembly and function of DNA double-strand break repair foci in mammalian cells. DNA Repair, 2010, 9, 1219-1228.	1.3	288
3	Novel BRCA1/2 mutations in Serbian breast and breast–ovarian cancer patients with hereditary predisposition. Cancer Genetics and Cytogenetics, 2010, 202, 27-32.	1.0	7
4	DNA double-strand break signaling and human disorders. Genome Integrity, 2010, 1, 15.	1.0	63
5	BRCA1 16 years later: DNA damageâ€induced BRCA1 shuttling. FEBS Journal, 2010, 277, 3079-3085.	2.2	35
6	Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumour cells and induction of complex DNA structural alterations. British Journal of Cancer, 2010, 103, 239-248.	2.9	38
8	Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Reviews Molecular Cell Biology, 2010, 11, 196-207.	16.1	779
9	Ubiquitin signalling in DNA replication and repair. Nature Reviews Molecular Cell Biology, 2010, 11, 479-489.	16.1	261
10	PI 3 Kinase Related Kinases-Independent Proteolysis of BRCA1 Regulates Rad51 Recruitment during Genotoxic Stress in Human Cells. PLoS ONE, 2010, 5, e14027.	1.1	13
11	Differential Dynamics of ATR-Mediated Checkpoint Regulators. Journal of Nucleic Acids, 2010, 2010, 1-16.	0.8	8
12	More Modifiers Move on DNA Damage. Cancer Research, 2010, 70, 3861-3863.	0.4	30
13	BRCA1 modulates the expression of hnRNPA2B1 and KHSRP. Cell Cycle, 2010, 9, 4666-4673.	1.3	30
14	RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage. Cancer Research, 2010, 70, 8467-8474.	0.4	9
15	BRCA1 regulation of base excision repair pathway. Cell Cycle, 2010, 9, 2471-2472.	1.3	18
16	The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer. Advances in Cancer Research, 2010, 108, 73-112.	1.9	980
17	The DNA Damage Response: Making It Safe to Play with Knives. Molecular Cell, 2010, 40, 179-204.	4.5	3,563
18	Structure–Activity Relationship Studies To Probe the Phosphoprotein Binding Site on the Carboxy Terminal Domains of the Breast Cancer Susceptibility Gene 1. Journal of Medicinal Chemistry, 2011, 54, 4264-4268.	2.9	17
19	Predictive molecular markers of anthracycline effectiveness in early breast cancer. European Journal of Cancer, Supplement, 2011, 9, 16-21.	2.2	1

		CITATION REPORT		
#	ARTICLE		IF	CITATIONS
20	BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature, 20	011, 477, 179-184.	13.7	403
22	Impact of BRCA1 BRCT Domain Missense Substitutions on Phosphopeptide Recognitio 2011, 50, 4579-4589.	n. Biochemistry,	1.2	42
23	Comparative analysis of nuclear estrogen receptor alpha and beta interactomes in brea Molecular BioSystems, 2011, 7, 667-676.	ıst cancer cells.	2.9	39
24	Oncogenic Ras Regulates BRIP1 Expression to Induce Dissociation of BRCA1 from Chrc DNA Repair, and Promote Senescence. Developmental Cell, 2011, 21, 1077-1091.	matin, Inhibit	3.1	82
25	Cdk1 and BRCA1 target $\hat{I}^3$ -tubulin to microtubule domains. Biochemical and Biophysica Communications, 2011, 414, 240-245.	al Research	1.0	11
26	miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PA Molecular Cell, 2011, 41, 210-220.	RP Inhibitors.	4.5	409
27	Oxidative stress induced carbonylation in human plasma. Journal of Proteomics, 2011,	74, 2395-2416.	1.2	37
28	BRCA1/BARD1 complex interacts with steroidogenic factor 1—A potential mechanisn aromatase expression by BRCA1. Journal of Steroid Biochemistry and Molecular Biology	n for regulation of y, 2011, 123, 71-78.	1.2	3
30	A DNA Repair Protein BRCA1 as a Potentially Molecular Target for the Anticancer Platin Cisplatin. , 2011, , .	um Drug		0
31	Biology of BRCA1 and BRCA2 genes and implications for cancer management. , 0, , 57-	74.		0
32	DNA Double-Strand Breaks Repair and Signaling of Human Gliomas and Normal Brain C to Radiation: Potential Impact of the ATM-and BRCA1- Dependent Pathways. , 2011, , .	ells in Response		1
33	The genetics of breast cancer: risk factors for disease. The Application of Clinical Genet	ics, 2011, 4, 11.	1.4	32
34	Posttranslational Modifications of Rad51 Protein and Its Direct Partners: Role and Effect Homologous Recombination $\hat{a} \in$ Mediated DNA Repair. , 2011, , .	ct on		5
35	Homologs of Breast Cancer Genes in Plants. Frontiers in Plant Science, 2011, 2, 19.		1.7	58
36	BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative by Breast Disease, 2011, 32, 85-97.	reast cancer.	0.4	25
37	ãf'ãf^é⁰ä¼åãf—ãfãf¢ãf¼ã,¿ãf¼ã«å²åœ¨ã™ã,‹é‡è <b>¤</b> GGAAé…å^—ã®ç"Ÿç‰©å¦çš,,å¹	∕2¹å‰². Yakugaku Zasshi,	2 <b>0</b> 1d, 131	, <b>\$787-18</b> 0
38	Establishment of a Southern Breast Cancer Cohort. Breast Journal, 2011, 17, 281-288.		0.4	11
39	RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour supproncogenesis. Nature Reviews Cancer, 2011, 11, 629-643.	ression and	12.8	347

щ		IF	CITATIONS
#	ARTICLE	IF	CHATIONS
40	Molecular Mechanisms of Mutagenesis, 2011, 711, 73-86.	0.4	117
41	Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacology, 2011, 11, 7.	0.4	43
42	SUMOylation and de UMOylation in response to DNA damage. FEBS Letters, 2011, 585, 2891-2896.	1.3	74
43	The ubiquitin―and SUMOâ€dependent signaling response to DNA doubleâ€strand breaks. FEBS Letters, 2011, 585, 2914-2919.	1.3	97
44	BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance. Cancer Cell, 2011, 20, 797-809.	7.7	228
45	"Ring-Fencing―BRCA1 Tumor Suppressor Activity. Cancer Cell, 2011, 20, 693-695.	7.7	2
46	Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 41-50.	1.0	19
47	Inherited Mutations in Breast Cancer Genes—Risk and Response. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 3-15.	1.0	56
48	The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Research and Treatment, 2011, 126, 203-209.	1.1	29
49	Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Research and Treatment, 2011, 127, 871-877.	1.1	0
50	Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Research and Treatment, 2011, 130, 993-1002.	1.1	59
51	DNA double-strand break repair in Caenorhabditis elegans. Chromosoma, 2011, 120, 1-21.	1.0	59
52	Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature. Journal of Biological Inorganic Chemistry, 2011, 16, 217-226.	1.1	9
53	The possible functions of duplicated ets (GGAA) motifs located near transcription start sites of various human genes. Cellular and Molecular Life Sciences, 2011, 68, 2039-2051.	2.4	19
54	New insights into the prevention and treatment of familial breast cancer. Journal of Surgical Oncology, 2011, 103, 294-298.	0.8	5
55	<i>ERCC5</i> / <i>XPG</i> , <i>ERCC1,</i> and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer, 2011, 117, 3445-3456.	2.0	57
56	Assessment of human nter and cter <i>&gt;BRCA1</i> mutations using growth and localization assays in yeast. Human Mutation, 2011, 32, 1470-1480.	1.1	15
57	Protein phosphatase 1 regulators in DNA damage signaling. Cell Cycle, 2011, 10, 1356-1362.	1.3	32

#	Article	IF	CITATIONS
58	BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity. Science, 2011, 334, 525-528.	6.0	212
59	The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes and Development, 2011, 25, 2158-2172.	2.7	387
60	MDC1 directs chromosome-wide silencing of the sex chromosomes in male germ cells. Genes and Development, 2011, 25, 959-971.	2.7	156
61	Uveal Melanoma and <i>BRCA1</i> / <i>BRCA2</i> Genes: A Relationship That Needs Further Investigation. Journal of Clinical Oncology, 2011, 29, e827-e829.	0.8	22
62	In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer: Basic and Clinical Research, 2011, 5, BCBCR.S8184.	0.6	5
63	Critical Role of Monoubiquitination of Histone H2AX Protein in Histone H2AX Phosphorylation and DNA Damage Response*. Journal of Biological Chemistry, 2011, 286, 30806-30815.	1.6	69
64	Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes and Development, 2011, 25, 409-433.	2.7	927
65	BRCC36A is epistatic to BRCA1 in DNA crosslink repair and homologous recombination in Arabidopsis thaliana. Nucleic Acids Research, 2011, 39, 146-154.	6.5	200
66	A Genome-Wide RNAi Screen Identifies Core Components of the G <sub>2</sub> -M DNA Damage Checkpoint. Science Signaling, 2011, 4, rs1.	1.6	48
68	Interferon Antagonist NSs of La Crosse Virus Triggers a DNA Damage Response-like Degradation of Transcribing RNA Polymerase II. Journal of Biological Chemistry, 2011, 286, 3681-3692.	1.6	71
69	Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle, 2011, 10, 3598-3607.	1.3	31
70	The Epistatic Relationship between BRCA2 and the Other RAD51 Mediators in Homologous Recombination. PLoS Genetics, 2011, 7, e1002148.	1.5	60
71	The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers, 2011, 3, 1426-1453.	1.7	35
72	MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination. Journal of Cell Science, 2012, 125, 6049-6057.	1.2	36
73	Altered DNA Binding and Amplification of Human Breast Cancer Suppressor Gene BRCA1 Induced by a Novel Antitumor Compound, [Ru(î·6-p-phenylethacrynate)Cl2(pta)]. International Journal of Molecular Sciences, 2012, 13, 13183-13202.	1.8	20
74	The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations. Scientifica, 2012, 2012, 1-15.	0.6	32
75	A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer. International Journal of Molecular Sciences, 2012, 13, 14898-14916.	1.8	19
76	BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. Journal of Cell Biology, 2012, 197, 201-208.	2.3	163

#	Article	IF	CITATIONS
77	RAS, cellular senescence and transformation. Small GTPases, 2012, 3, 163-167.	0.7	7
78	Targeting Homologous Recombination Repair in Cancer. , 2012, , 119-160.		7
79	Ring Finger Nuclear Factor RNF168 Is Important for Defects in Homologous Recombination Caused by Loss of the Breast Cancer Susceptibility Factor BRCA1. Journal of Biological Chemistry, 2012, 287, 40618-40628.	1.6	44
80	Distinct Roles of FANCO/RAD51C Protein in DNA Damage Signaling and Repair. Journal of Biological Chemistry, 2012, 287, 3366-3380.	1.6	65
81	BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13650-13655.	3.3	121
82	The F-box Protein FBXO44 Mediates BRCA1 Ubiquitination and Degradation. Journal of Biological Chemistry, 2012, 287, 41014-41022.	1.6	45
83	Hereditary ovarian cancer and two-compartment tumor metabolism. Cell Cycle, 2012, 11, 4152-4166.	1.3	53
84	The C-terminal Proteolytic Fragment of the Breast Cancer Susceptibility Type 1 Protein (BRCA1) Is Degraded by the N-end Rule Pathway. Journal of Biological Chemistry, 2012, 287, 7495-7502.	1.6	26
85	BRCA1-directed, enhanced and aberrant homologous recombination. Cell Cycle, 2012, 11, 687-694.	1.3	20
86	BRCA1 and MicroRNAs: Emerging Networks and Potential Therapeutic Targets. Molecules and Cells, 2012, 34, 425-432.	1.0	46
87	Characterizing Ubiquitination Sites by Peptide-based Immunoaffinity Enrichment. Molecular and Cellular Proteomics, 2012, 11, 1529-1540.	2.5	55
88	BRCA1 as tumor suppressor: lord without its RING?. Breast Cancer Research, 2012, 14, 306.	2.2	8
89	Playing the End Game: DNA Double-Strand Break Repair Pathway Choice. Molecular Cell, 2012, 47, 497-510.	4.5	1,349
91	Nonenzymatic Polymerization of Ubiquitin: Singleâ€5tep Synthesis and Isolation of Discrete Ubiquitin Oligomers. Angewandte Chemie - International Edition, 2012, 51, 13085-13088.	7.2	55
92	DNA repair genes BRCA1 and DNA-PKcs have great potential in radiation therapy. Chinese-German Journal of Clinical Oncology, 2012, 11, 683-688.	0.1	1
93	Three-dimensional imaging reveals the spatial separation of γH2AX–MDC1–53BP1 and RNF8–RNF168–BRCA1-A complexes at ionizing radiation-induced foci. Radiotherapy and Oncology, 2012, 103, 415-420.	0.3	14
94	Activation of the BRCA1/Chk1/p53/p21Cip1/Waf1 pathway by nitric oxide and cell cycle arrest in human neuroblastoma NB69 cells. Nitric Oxide - Biology and Chemistry, 2012, 26, 182-191.	1.2	21
95	Gene regulation in response to DNA damage. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2012, 1819, 154-165.	0.9	58

#	Article	IF	CITATIONS
96	Homologous Recombination in Eukaryotes. Progress in Molecular Biology and Translational Science, 2012, 110, 155-206.	0.9	28
97	Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes. Future Medicinal Chemistry, 2012, 4, 51-72.	1.1	21
98	PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells. Biochemical Pharmacology, 2012, 84, 1318-1331.	2.0	24
99	Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography. Mutation Research - Reviews in Mutation Research, 2012, 751, 158-246.	2.4	307
100	The WSTF-ISWI Chromatin Remodeling Complex Transiently Associates with the Human Inactive X Chromosome during Late S-Phase Prior to BRCA1 and Î <sup>3</sup> -H2AX. PLoS ONE, 2012, 7, e50023.	1.1	9
101	Protein Conformational Switches: From Nature to Design. Chemistry - A European Journal, 2012, 18, 7984-7999.	1.7	120
102	BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. Cancer and Metastasis Reviews, 2012, 31, 131-142.	2.7	11
103	Chromosome instability and deregulated proliferation: an unavoidable duo. Cellular and Molecular Life Sciences, 2012, 69, 2009-2024.	2.4	36
104	Sex chromosome inactivation in germ cells: emerging roles of DNA damage response pathways. Cellular and Molecular Life Sciences, 2012, 69, 2559-2572.	2.4	88
105	Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFήB pathway. Breast Cancer Research and Treatment, 2012, 134, 41-51.	1.1	34
106	BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Reviews Cancer, 2012, 12, 68-78.	12.8	1,102
107	The <i>In Vivo</i> Dynamic Organization of <scp>BRCA1â€A</scp> Complex Proteins at <scp>DNA</scp> Damageâ€Induced Nuclear Foci. Traffic, 2012, 13, 800-814.	1.3	17
108	BRCA1 tumor suppressor network: focusing on its tail. Cell and Bioscience, 2012, 2, 6.	2.1	57
109	Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1499-1507.	0.7	11
110	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cellular and Molecular Life Sciences, 2012, 69, 223-245.	2.4	59
111	The Transcription Factor FOXM1 (Forkhead box M1). Advances in Cancer Research, 2013, 118, 97-398.	1.9	135
112	The growing complexity of HIF-1α's role in tumorigenesis: DNA repair and beyond. Oncogene, 2013, 32, 3569-3576.	2.6	72
113	Nuclear Medicine Therapy. , 2013, , .		5

#	Article	IF	CITATIONS
114	RNF111-Dependent Neddylation Activates DNA Damage-Induced Ubiquitination. Molecular Cell, 2013, 49, 897-907.	4.5	107
115	BRCA1 and CtIP suppress long-tract gene conversion between sister chromatids. Nature Communications, 2013, 4, 2404.	5.8	56
116	FOXM1 (Forkhead box M1) in Tumorigenesis. Advances in Cancer Research, 2013, 119, 191-419.	1.9	146
117	Structural Basis for the BRCA1 BRCT Interaction with the Proteins ATRIP and BAAT1. Biochemistry, 2013, 52, 7618-7627.	1.2	13
118	The histone demethylase LSD1/KDM1A promotes the DNA damage response. Journal of Cell Biology, 2013, 203, 457-470.	2.3	112
119	To spread or not to spread—chromatin modifications in response to DNA damage. Current Opinion in Genetics and Development, 2013, 23, 156-165.	1.5	46
120	Pyrimidine base damage is increased in women with BRCA mutations. Cancer Letters, 2013, 338, 267-270.	3.2	2
121	A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma. Carcinogenesis, 2013, 34, 2309-2313.	1.3	54
122	Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hereditary Cancer in Clinical Practice, 2013, 11, 12.	0.6	48
123	Detection of a novel mutation in exon 20 of the BRCA1 gene. Cellular and Molecular Biology Letters, 2013, 18, 631-8.	2.7	4
124	Chromatin structure in double strand break repair. DNA Repair, 2013, 12, 800-810.	1.3	48
125	Regulation of the DNA damage response on male meiotic sex chromosomes. Nature Communications, 2013, 4, 2105.	5.8	28
126	Heterochromatin instability in cancer: From the Barr body to satellites and the nuclear periphery. Seminars in Cancer Biology, 2013, 23, 99-108.	4.3	94
127	BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny. Genes and Development, 2013, 27, 39-51.	2.7	33
128	Derailed Estrogen Signaling and Breast Cancer: An Authentic Couple. Endocrine Reviews, 2013, 34, 1-32.	8.9	104
129	MicroRNA biogenesis: regulating the regulators. Critical Reviews in Biochemistry and Molecular Biology, 2013, 48, 51-68.	2.3	261
130	High LET Radiation Amplifies Centrosome Overduplication Through a Pathway of γ-Tubulin Monoubiquitination. International Journal of Radiation Oncology Biology Physics, 2013, 86, 358-365.	0.4	6
131	A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. International Journal of Cancer, 2013, 133, 2759-2768.	2.3	46

#	Article	IF	CITATIONS
132	Repair with a twist. Nature Reviews Molecular Cell Biology, 2013, 14, 268-268.	16.1	0
133	Mechanisms for Structural Variation in the Human Genome. Current Genetic Medicine Reports, 2013, 1, 81-90.	1.9	29
134	BRCA1 is a negative modulator of the PRC2 complex. EMBO Journal, 2013, 32, 1584-1597.	3.5	104
135	Serbian high-risk families: extensive results on BRCA mutation spectra and frequency. Journal of Human Genetics, 2013, 58, 501-507.	1.1	10
136	Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation. Cancer Cell, 2013, 23, 693-704.	7.7	261
137	FancJ regulates interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Biology Open, 2013, 2, 1022-1031.	0.6	18
138	Response to DNA damage: why do we need to focus on protein phosphatases?. Frontiers in Oncology, 2013, 3, 8.	1.3	32
139	ATM–Dependent MiR-335 Targets CtIP and Modulates the DNA Damage Response. PLoS Genetics, 2013, 9, e1003505.	1.5	42
140	Put a RING on it: regulation and inhibition of RNF8 and RNF168 RING finger E3 ligases at DNA damage sites. Frontiers in Genetics, 2013, 4, 128.	1.1	35
141	The chromatin remodeling protein BRG1 modulates BRCA1 response to UV irradiation by regulating ATR/ATM activation. Frontiers in Oncology, 2013, 3, 7.	1.3	20
142	RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair. Journal of Biological Chemistry, 2013, 288, 11135-11143.	1.6	235
143	BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress. Cell Cycle, 2013, 12, 2255-2265.	1.3	23
144	Novel DNA Damage Checkpoints Mediating Cell Death Induced by the NEDD8-Activating Enzyme Inhibitor MLN4924. Cancer Research, 2013, 73, 225-234.	0.4	87
145	Radiosensitization of esophageal cancer cells <scp>ECA109</scp> by knockdown of <scp>H2AX</scp> . Thoracic Cancer, 2013, 4, 254-263.	0.8	3
146	<i>BRCA1</i> promotes the ubiquitination of PCNA and recruitment of translesion polymerases in response to replication blockade. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13558-13563.	3.3	42
147	Co-operation of BRCA1 and POH1 relieves the barriers posed by 53BP1 and RAP80 to resection. Nucleic Acids Research, 2013, 41, 10298-10311.	6.5	99
148	The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression. Journal of Cell Biology, 2013, 201, 693-707.	2.3	71
149	BRCA1 and Its Network of Interacting Partners. Biology, 2013, 2, 40-63.	1.3	43

#	Article	IF	CITATIONS
150	BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy. PLoS ONE, 2013, 8, e52589.	1.1	30
151	BRCA1 Haploinsufficiency Leads to Altered Expression of Genes Involved in Cellular Proliferation and Development. PLoS ONE, 2014, 9, e100068.	1.1	16
152	Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified <i>BRCA1</i> . Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S14224.	0.6	1
153	BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nature Communications, 2014, 5, 5496.	5.8	129
154	NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels. Cancer Biology and Therapy, 2014, 15, 533-543.	1.5	35
155	BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Cell Cycle, 2014, 13, 3685-3697.	1.3	17
156	Suppression of BRCA1 sensitizes cells to proteasome inhibitors. Cell Death and Disease, 2014, 5, e1580.	2.7	21
157	BRCA1 modulates the autophosphorylation status of DNA-PKcs in S phase of the cell cycle. Nucleic Acids Research, 2014, 42, 11487-11501.	6.5	42
158	Using epigenomic studies in monozygotic twins to improve our understanding ofÂcancer. Epigenomics, 2014, 6, 299-309.	1.0	14
159	BRCA1 Accelerates CtIP-Mediated DNA-End Resection. Cell Reports, 2014, 9, 451-459.	2.9	207
1(0			
160	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127.	6.5	72
160	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127. A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function. Nucleic Acids Research, 2014, 42, e164-e164.	6.5 6.5	72 32
161 162	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127.         A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function. Nucleic Acids Research, 2014, 42, e164-e164.         Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes and Development, 2014, 28, 1957-1975.	6.5 6.5 2.7	72 32 86
160 161 162 163	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127.         A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function. Nucleic Acids Research, 2014, 42, e164-e164.         Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes and Development, 2014, 28, 1957-1975.         Omics Approaches in Breast Cancer., 2014,	6.5 6.5 2.7	72 32 86 10
160 161 162 163 164	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127.A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function. Nucleic Acids Research, 2014, 42, e164-e164.Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes and Development, 2014, 28, 1957-1975.Omics Approaches in Breast Cancer., 2014, .Breast Cancer Genomics., 2014, .	6.5 6.5 2.7	<ul> <li>72</li> <li>32</li> <li>86</li> <li>10</li> <li>0</li> </ul>
<ol> <li>160</li> <li>161</li> <li>162</li> <li>163</li> <li>164</li> <li>165</li> </ol>	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127.A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function. Nucleic Acids Research, 2014, 42, e164-e164.Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes and Development, 2014, 28, 1957-1975.Omics Approaches in Breast Cancer., 2014, ,.Breast Cancer Genomics., 2014, ,53-103.NF-κB is a critical mediator of BRCA1-induced chemoresistance. Oncogene, 2014, 33, 713-723.	<ul> <li>6.5</li> <li>2.7</li> <li>2.6</li> </ul>	<ul> <li>72</li> <li>32</li> <li>86</li> <li>10</li> <li>0</li> <li>41</li> </ul>
<ol> <li>160</li> <li>161</li> <li>162</li> <li>163</li> <li>164</li> <li>165</li> <li>166</li> </ol>	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127.A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function. Nucleic Acids Research, 2014, 42, e164-e164.Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes and Development, 2014, 28, 1957-1975.Omics Approaches in Breast Cancer., 2014, ,.Breast Cancer Genomics., 2014, ,53-103.NF-Î*B is a critical mediator of BRCA1-induced chemoresistance. Oncogene, 2014, 33, 713-723.Opportunities and hurdles in the treatment of BRCA1-related breast cancer. Oncogene, 2014, 33, 3753-3763.	<ul> <li>6.5</li> <li>6.5</li> <li>2.7</li> <li>2.6</li> </ul>	<ul> <li>72</li> <li>32</li> <li>86</li> <li>10</li> <li>0</li> <li>41</li> <li>30</li> </ul>

#	Article	IF	CITATIONS
168	Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks. EMBO Journal, 2014, 33, 862-877.	3.5	75
169	The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2. FEMS Yeast Research, 2014, 14, 2-16.	1.1	51
170	BRCA1 establishes DNA damage signaling and pericentric heterochromatin of the X chromosome in male meiosis. Journal of Cell Biology, 2014, 205, 663-675.	2.3	74
171	Strand-Specific Analysis Shows Protein Binding at Replication Forks and PCNA Unloading from Lagging Strands when Forks Stall. Molecular Cell, 2014, 56, 551-563.	4.5	153
172	BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability. Cancer Research, 2014, 74, 2773-2784.	0.4	94
173	SUMOylation of ATRIP potentiates DNA damage signaling by boosting multiple protein interactions in the ATR pathway. Genes and Development, 2014, 28, 1472-1484.	2.7	57
174	BRCA1 Pathway Function in Basal-Like Breast Cancer Cells. Molecular and Cellular Biology, 2014, 34, 3828-3842.	1.1	40
175	Quality control of homologous recombination. Cellular and Molecular Life Sciences, 2014, 71, 3779-3797.	2.4	29
176	Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry. Familial Cancer, 2014, 13, 431-435.	0.9	4
177	A germline mutation in the BRCA13'UTR predicts Stage IV breast cancer. BMC Cancer, 2014, 14, 421.	1.1	14
178	Loss of BRCA1 impairs centromeric cohesion and triggers chromosomal instability. FASEB Journal, 2014, 28, 5250-5261.	0.2	18
179	Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice. Nature Communications, 2014, 5, 3561.	5.8	143
180	Cell cycle-dependent inhibition of 53BP1 signaling by BRCA1. Cell Discovery, 2015, 1, 15019.	3.1	59
181	Effects of Radiation Therapy on Breast Epithelial Cells in <i>BRCA1/2</i> Mutation Carriers. Breast Cancer: Basic and Clinical Research, 2015, 9, BCBCR.S26774.	0.6	3
182	Alphaâ€phellandreneâ€induced DNA damage and affect DNA repair protein expression in WEHIâ€3 murine leukemia cells <i>in vitro</i> . Environmental Toxicology, 2015, 30, 1322-1330.	2.1	14
183	Transcriptional Regulation of the Human Genes that Encode DNA Repair- and Mitochondrial Function-Associated Proteins. , 2015, , .		6
184	Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy. Biomolecules, 2015, 5, 1652-1670.	1.8	110
185	A porcine model system of BRCA1 driven breast cancer. Frontiers in Genetics, 2015, 6, 269.	1.1	8

	CITATION	LFORT	
#	Article	IF	Citations
186	DNA repair mechanisms in cancer development and therapy. Frontiers in Genetics, 2015, 6, 157.	1.1	240
187	Ubiquitylation, neddylation and the DNA damage response. Open Biology, 2015, 5, 150018.	1.5	117
188	DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Seminars in Radiation Oncology, 2015, 25, 237-250.	1.0	59
189	ATM-dependent Phosphorylation of the Fanconi Anemia Protein PALB2 Promotes the DNA Damage Response. Journal of Biological Chemistry, 2015, 290, 27545-27556.	1.6	18
190	Damage-induced BRCA1 phosphorylation by Chk2 contributes to the timing of end resection. Cell Cycle, 2015, 14, 437-448.	1.3	33
191	The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. Cancer Causes and Control, 2015, 26, 333-344.	0.8	40
192	BRCA1 Recruitment to Transcriptional Pause Sites Is Required for R-Loop-Driven DNA Damage Repair. Molecular Cell, 2015, 57, 636-647.	4.5	363
193	Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2157-2162.	3.3	13
194	Peptide Library Approach to Uncover Phosphomimetic Inhibitors of the BRCA1 C-Terminal Domain. ACS Chemical Biology, 2015, 10, 1198-1208.	1.6	35
195	Double-strand break repair on sex chromosomes: challenges during male meiotic prophase. Cell Cycle, 2015, 14, 516-525.	1.3	37
196	Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. Cancer Research, 2015, 75, 1311-1321.	0.4	83
197	From candidate gene studies to GWAS and post-GWAS analyses in breast cancer. Current Opinion in Genetics and Development, 2015, 30, 32-41.	1.5	83
198	Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 498-504.	1.1	42
199	Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nature Communications, 2015, 6, 7505.	5.8	101
200	Malignant mesothelioma as an oxidative stress-induced cancer: An update. Free Radical Biology and Medicine, 2015, 86, 166-178.	1.3	77
201	BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection. Virology Journal, 2015, 12, 40.	1.4	12
202	BRCA1: Beyond double-strand break repair. DNA Repair, 2015, 32, 165-171.	1.3	13
203	Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding. Cancer Research, 2015, 75, 2699-2707.	0.4	22

#	Article	IF	CITATIONS
204	Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins. Cold Spring Harbor Perspectives in Biology, 2015, 7, a016600.	2.3	636
205	Genotype/Phenotype Correlations in Patients with Hereditary Breast Cancer. Breast Care, 2015, 10, 22-26.	0.8	17
206	A Comprehensive Approach to the Identification and Management of the BRCA Patient. Obstetrical and Gynecological Survey, 2015, 70, 131-143.	0.2	6
207	Protein stability versus function: effects of destabilizing missense mutations on <i>BRCA1</i> DNA repair activity. Biochemical Journal, 2015, 466, 613-624.	1.7	12
208	p53 suppresses hyper-recombination by modulating BRCA1 function. DNA Repair, 2015, 33, 60-69.	1.3	23
209	BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. British Journal of Cancer, 2015, 112, 688-692.	2.9	18
211	The de-ubiquitylating enzymes USP26 and USP37 regulate homologous recombination by counteracting RAP80. Nucleic Acids Research, 2015, 43, 6919-6933.	6.5	64
212	Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. Journal of Cellular Biochemistry, 2015, 116, 2824-2839.	1.2	19
213	MERIT40 cooperates with BRCA2 to resolve DNA interstrand cross-links. Genes and Development, 2015, 29, 1955-1968.	2.7	22
214	DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nature Communications, 2015, 6, 8897.	5.8	143
215	Considerations for Comprehensive Assessment of Genetic Predisposition in Familial Breast Cancer. Breast Journal, 2015, 21, 67-75.	0.4	14
216	DNA repair after X-irradiation: lessons from plants. Mutagenesis, 2015, 30, 45-50.	1.0	13
217	The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy. Annual Review of Medicine, 2015, 66, 129-143.	5.0	403
218	The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population. Tumor Biology, 2015, 36, 393-397.	0.8	18
219	BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function. Oncogene, 2015, 34, 4333-4346.	2.6	63
220	Targeting BRCA1â€BER deficient breast cancer by ATM or DNAâ€PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular Oncology, 2015, 9, 204-217.	2.1	72
221	From pathways to networks: Connecting dots by establishing protein–protein interaction networks in signaling pathways using affinity purification and mass spectrometry. Proteomics, 2015, 15, 188-202.	1.3	20
222	Targeting of DNA Damage Signaling Pathway Induced Senescence and Reduced Migration of Cancer cells. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 701-713.	1.7	16

#	Article	IF	Citations
223	"DNA Binding Region―of BRCA1 Affects Genetic Stability through modulating the Intra-S-Phase Checkpoint. International Journal of Biological Sciences, 2016, 12, 133-143.	2.6	23
224	Writers, Readers, and Erasers of Histone Ubiquitylation in DNA Double-Strand Break Repair. Frontiers in Genetics, 2016, 7, 122.	1.1	35
225	Cell Adhesion Molecules and Ubiquitination—Functions and Significance. Biology, 2016, 5, 1.	1.3	49
226	Repair of DNA Double-Strand Breaks in Heterochromatin. Biomolecules, 2016, 6, 47.	1.8	22
227	Tankyrases Promote Homologous Recombination and Check Point Activation in Response to DSBs. PLoS Genetics, 2016, 12, e1005791.	1.5	46
228	The SMC-5/6 Complex and the HIM-6 (BLM) Helicase Synergistically Promote Meiotic Recombination Intermediate Processing and Chromosome Maturation during Caenorhabditis elegans Meiosis. PLoS Genetics, 2016, 12, e1005872.	1.5	38
229	BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells. Molecular Cell, 2016, 63, 277-292.	4.5	61
230	Knockdown of COUPâ€TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells. International Journal of Cancer, 2016, 139, 1574-1585.	2.3	15
231	<scp>SLFN</scp> 11 inhibits checkpoint maintenance and homologous recombination repair. EMBO Reports, 2016, 17, 94-109.	2.0	116
232	BRCA1 inhibits AR–mediated proliferation of breast cancer cells through the activation of SIRT1. Scientific Reports, 2016, 6, 22034.	1.6	51
233	Unsolved mystery: the role of BRCA1 in DNA end-joining. Journal of Radiation Research, 2016, 57, i18-i24.	0.8	29
234	Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization. Cell Cycle, 2016, 15, 2723-2731.	1.3	9
235	A genome-wide screening uncovers the role of CCAR2 as an antagonist of DNA end resection. Nature Communications, 2016, 7, 12364.	5.8	40
236	RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation. Nature Communications, 2016, 7, 12638.	5.8	35
237	Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage. Acta Biochimica Et Biophysica Sinica, 2016, 48, 658-664.	0.9	28
238	The Lys63-deubiquitylating Enzyme BRCC36 Limits DNA Break Processing and Repair. Journal of Biological Chemistry, 2016, 291, 16197-16207.	1.6	35
239	Persistent Activation of NF-l̂ºB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. Cell Stem Cell, 2016, 19, 52-65.	5.2	85
240	Uninterrupted Sedentary Behavior Downregulates <i>BRCA1</i> Gene Expression. Cancer Prevention Research, 2016, 9, 83-88.	0.7	13

		CITATION REPORT		
#	Article		IF	Citations
241	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2	2016, 30, 355-385.	2.7	416
242	Trabectedin is a promising antitumour agent for synovial sarcoma. Journal of Chemothe 417-424.	erapy, 2016, 28,	0.7	3
243	BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific Cycle, 2016, 15, 621-627.	: cancer. Cell	1.3	22
244	Deregulation of F-box proteins and its consequence on cancer development, progression metastasis. Seminars in Cancer Biology, 2016, 36, 33-51.	on and	4.3	48
245	BRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP Dephosphorylation. Cell Reports, 2017, 18, 520-532.	1	2.9	136
246	The Histone Variant MacroH2A1 Is a BRCA1ÂUbiquitin Ligase Substrate. Cell Reports, 2	2017, 19, 1758-1766.	2.9	35
247	Histone ubiquitination in the DNA damage response. DNA Repair, 2017, 56, 92-101.		1.3	167
248	Ductal invasive carcinoma arising within atypical microglandular adenosis in a patient v mutation: A case report. Human Pathology: Case Reports, 2017, 8, 41-45.	vith BRCA-1	0.2	0
249	DNA damage response and autophagy in the degeneration of retinal pigment epithelial cells—Implications for age-related macular degeneration (AMD). Ageing Research Rev 64-77.	l views, 2017, 36,	5.0	55
250	Functional analysis of BRCT missense mutations in BRCA1‑mutated Chinese Han fam Oncology Letters, 2017, 14, 5839-5844.	nilial breast cancer.	0.8	1
251	Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysf∟ BRCA1 in Alzheimer's disease. Proceedings of the National Academy of Sciences of America, 2017, 114, E9645-E9654.	inction of the United States of	3.3	72
252	Recent progress in mass spectrometry proteomics for biomedical research. Science Chi Sciences, 2017, 60, 1093-1113.	ina Life	2.3	97
253	Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines. Drugs in 569-583.	R and D, 2017, 17,	1.1	5
254	A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple breast cancer, especially after radiotherapy. Breast Cancer Research and Treatment, 20	-negative 17, 166, 109-116.	1.1	12
255	Radiosensitizing activity of novel small molecule BRCA1 and DNA-PK inhibitors in lung a carcinoma. Journal of Radiation Research and Applied Sciences, 2017, 10, 204-213.	and colon	0.7	0
256	What can yeast tell us about breast cancer?. Cell Cycle, 2017, 16, 157-158.		1.3	1
257	Genetic variants in microRNAâ€binding sites of DNA repair genes as predictors of recur with squamous cell carcinoma of the oropharynx. International Journal of Cancer, 2017	rence in patients 7, 141, 1355-1364.	2.3	9
258	Managing BRCA Mutation Carriers. , 2017, , .			0

#	Article	IF	CITATIONS
259	Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. Journal of Hematology and Oncology, 2017, 10, 84.	6.9	23
260	TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects. Oncogene, 2017, 36, 820-828.	2.6	37
261	Prognostic and Predictive Significance of Base Excision Repair in Human Cancers. , 2017, , 609-662.		0
262	Low RAP80 mRNA Expression Correlates with Shorter Survival in Sporadic High-Grade Serous Ovarian Carcinoma. International Journal of Biological Markers, 2017, 32, 90-95.	0.7	1
263	Transcription Factors in Breast Cancer—Lessons From Recent Genomic Analyses and Therapeutic Implications. Advances in Protein Chemistry and Structural Biology, 2017, 107, 223-273.	1.0	14
264	53BP1 and BRCA1 control pathway choice for stalled replication restart. ELife, 2017, 6, .	2.8	64
265	Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. ELife, 2017, 6, .	2.8	81
266	Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET. Journal of Hepatology, 2018, 69, 79-88.	1.8	39
267	Caught with One's Zinc Fingers in the Genome Integrity Cookie Jar. Trends in Genetics, 2018, 34, 313-325.	2.9	51
268	Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development. Scientific Reports, 2018, 8, 2731.	1.6	3
269	Multiple roles of singleâ€minded 2 in esophageal squamous cell carcinoma and its clinical implications. Cancer Science, 2018, 109, 1121-1134.	1.7	20
270	BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. Breast Cancer Research and Treatment, 2018, 167, 803-814.	1.1	36
271	BRCA2 controls DNA:RNA hybrid level at DSBs by mediating RNase H2 recruitment. Nature Communications, 2018, 9, 5376.	5.8	176
272	MSCs inhibit tumor progression and enhance radiosensitivity of breast cancer cells by down-regulating Stat3 signaling pathway. Cell Death and Disease, 2018, 9, 1026.	2.7	73
273	BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Reports, 2018, 24, 3513-3527.e7.	2.9	61
274	Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 3249.	1.8	7
275	Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?. PLoS ONE, 2018, 13, e0195497.	1.1	4
276	Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway. BMC Pharmacology & Toxicology, 2018, 19, 5.	1.0	8

#	Article	IF	CITATIONS
277	Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation. Cell Death and Differentiation, 2019, 26, 812-825.	5.0	32
278	Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer. Translational Oncology, 2019, 12, 1453-1460.	1.7	6
279	EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses <i>BRCA1</i> -mutated breast cancer. Nanomedicine, 2019, 14, 2315-2338.	1.7	17
280	Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer. Cell, 2019, 178, 135-151.e19.	13.5	60
281	Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment. Frontiers in Physiology, 2019, 10, 1144.	1.3	42
282	BRCA-1 depletion impairs pro-inflammatory polarization and activation of RAW 264.7 macrophages in a NF-κB-dependent mechanism. Molecular and Cellular Biochemistry, 2019, 462, 11-23.	1.4	3
283	Breast cancer. Nature Reviews Disease Primers, 2019, 5, 66.	18.1	1,620
284	Exploiting <scp>DNA</scp> repair defects in colorectal cancer. Molecular Oncology, 2019, 13, 681-700.	2.1	90
285	The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. Cancers, 2019, 11, 838.	1.7	160
286	Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers. Methods in Molecular Biology, 2019, 1999, 3-29.	0.4	3
287	BCL10 in cell survival after DNA damage. Clinica Chimica Acta, 2019, 495, 301-308.	0.5	7
288	Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. International Journal of Biological Sciences, 2019, 15, 962-972.	2.6	10
289	Propofol Alleviates DNA Damage Induced by Oxygen Glucose Deprivation and Reperfusion via FoxO1 Nuclear Translocation in H9c2 Cells. Frontiers in Physiology, 2019, 10, 223.	1.3	11
290	Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency. Scientific Reports, 2019, 9, 1644.	1.6	15
291	Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling. Advances in Protein Chemistry and Structural Biology, 2019, 115, 297-324.	1.0	21
292	Effect of single amino acid mutations on C-terminal domain of breast cancer susceptible protein 1. International Journal of Bioinformatics Research and Applications, 2019, 15, 305.	0.1	0
293	Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomedicine and Pharmacotherapy, 2019, 109, 195-207.	2.5	62
294	Breast cancer risk associated with BRCA1/2 variants in the Pakistani population. Breast Cancer, 2019, 26, 365-372.	1.3	6

#	Article	IF	CITATIONS
295	Design, Synthesis and Interaction of BRCA1 Peptide Fragments with RAD51(181–200). International Journal of Peptide Research and Therapeutics, 2020, 26, 121-128.	0.9	3
296	The role of E3 ubiquitin ligase HECTD3 in cancer and beyond. Cellular and Molecular Life Sciences, 2020, 77, 1483-1495.	2.4	18
297	Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity. Cellular and Molecular Life Sciences, 2020, 77, 19-33.	2.4	65
298	Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays. Biological Procedures Online, 2020, 22, 23.	1.4	14
299	L ARP7 Is a BRCA1ÂUbiquitinase Substrate and Regulates Genome Stability and Tumorigenesis. Cell Reports, 2020, 32, 107974.	2.9	13
300	BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. Cancer Research, 2020, 80, 4601-4609.	0.4	30
301	FANCJ compensates for RAP80 deficiency and suppresses genomic instability induced by interstrand cross-links. Nucleic Acids Research, 2020, 48, 9161-9180.	6.5	7
302	PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. Chinese Clinical Oncology, 2020, 9, 51-51.	0.4	4
303	BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites. EMBO Journal, 2020, 39, e104133.	3.5	41
304	Sequence specificity, energeticsÂand mechanism of mismatch recognition by DNA damage sensing protein Rad4/XPC. Nucleic Acids Research, 2020, 48, 2246-2257.	6.5	11
305	Limiting the DNA Double-Strand Break Resectosome for Genome Protection. Trends in Biochemical Sciences, 2020, 45, 779-793.	3.7	27
306	Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining. Journal of Ovarian Research, 2020, 13, 27.	1.3	14
307	Classification of VUS and unclassified variants in BRCA1 BRCT repeats by molecular dynamics simulation. Computational and Structural Biotechnology Journal, 2020, 18, 723-736.	1.9	63
308	Recent progress on the role and molecular mechanism of chicken ovalbumin upstream promoter-transcription factor II in cancer. Journal of International Medical Research, 2020, 48, 030006052091923.	0.4	Ο
309	Cell Cycle and DNA Repair Regulation in the Damage Response: Protein Phosphatases Take Over the Reins. International Journal of Molecular Sciences, 2020, 21, 446.	1.8	57
310	BRCA1 and homologous recombination: implications from mouse embryonic development. Cell and Bioscience, 2020, 10, 49.	2.1	24
311	Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes. Cancers, 2020, 12, 903.	1.7	14
312	BRCA1-BARD1 regulates transcription through BRD4 in <i>Xenopus</i> nucleoplasmic extract. Nucleic Acids Research, 2021, 49, 3263-3273.	6.5	7

ARTICLE IF CITATIONS # Genetic Influences in Breast Cancer Drug Resistance. Breast Cancer: Targets and Therapy, 2021, Volume 313 1.0 8 13, 59-85. A synergetic effect of BARD1 mutations on tumorigenesis. Nature Communications, 2021, 12, 1243. 314 5.8 BRCA1 and RNAi factors promote repair mediated by small RNAs and PALB2–RAD52. Nature, 2021, 591, 315 13.7 30 665-670. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. International Journal of 1.8 Molecular Sciences, 2021, 22, 3753. miRNA dysregulation is an emerging modulator of genomic instability. Seminars in Cancer Biology, 318 4.3 49 2021, 76, 120-131. BRCA1: a key player at multiple stages of homologous recombination in DNA double-strand break repair. Genome Instability & Disease, 2021, 2, 164-174. 319 New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer. Genes, 320 1.0 12 2021, 12, 723. In-Silico Analyses of Nonsynonymous Variants in the BRCA1 Gene. Biochemical Genetics, 2021, 59, 321 0.8 1506-1526. Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response. ELife, 323 2.8 11 2021, 10, . BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and 324 2.7 ovarian cancer. British Journal of Pharmacology, 2021, 178, 3627-3647. Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target. 325 1.7 11 Cancers, 2021, 13, 3438. Microenvironmental control of cell fate decisions in mammary gland development and cancer. 3.1 Developmental Cell, 2021, 56, 1875-1883. Altered regulation of <i>BRCA1</i> exon 11 splicing is associated with breast cancer risk in carriers of 327 1.1 7 <i>BRCA1</i> pathogenic variants. Human Mutation, 2021, 42, 1488-1502. The <i>trans</i> cell cycle effects of PARP inhibitors underlie their selectivity toward 2.7 BRCA1/2-deficient cells. Genes and Development, 2021, 35, 1271-1289. RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage. Nature 329 5.8 35 Communications, 2021, 12, 5016. ADAR-mediated RNA editing of DNA:RNA hybrids is required for DNA double strand break repair. Nature 5.8 30 Communications, 2021, 12, 5512. 331 H2AX in DNA Damage Response., 2011, , 3-33. 3 VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling. Journal of Clinical Investigation, 2011, 121, 3072-3087.

#	Article	IF	CITATIONS
334	BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. Journal of Clinical Investigation, 2016, 126, 2903-2918.	3.9	105
335	RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance. Journal of Clinical Investigation, 2016, 126, 3145-3157.	3.9	74
336	Sam68 Is Required for DNA Damage Responses via Regulating Poly(ADP-ribosyl)ation. PLoS Biology, 2016, 14, e1002543.	2.6	28
337	SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1. PLoS Genetics, 2017, 13, e1007031.	1.5	22
338	Dynamics of Response to Asynapsis and Meiotic Silencing in Spermatocytes from Robertsonian Translocation Carriers. PLoS ONE, 2013, 8, e75970.	1.1	15
339	The DNA damage response: Balancing the scale between cancer and ageing. Aging, 2010, 2, 900-907.	1.4	52
340	Mutations in the BRCT binding site of BRCA1 result in hyper-recombination. Aging, 2011, 3, 515-532.	1.4	40
341	A role of the 53BP1 protein in genome protection: structural and functional characteristics of 53BP1-dependent DNA repair. Aging, 2019, 11, 2488-2511.	1.4	16
342	Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes and Cancer, 2015, 6, 378-398.	0.6	28
343	BRCA1 and γH2AX as independent prognostic markers in oral squamous cell carcinoma. Oncoscience, 2014, 1, 383-391.	0.9	25
344	Association between <i>BRCA1</i> P871L polymorphism and cancer risk: evidence from a meta-analysis. Oncotarget, 2017, 8, 30587-30594.	0.8	3
345	Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. Oncotarget, 2015, 6, 617-632.	0.8	13
346	Association between vitamin D and ovarian cancer development in <i>BRCA1</i> mutation carriers. Oncotarget, 2020, 11, 4104-4114.	0.8	4
347	BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner. Oncotarget, 2015, 6, 7608-7618.	0.8	38
348	DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget, 2015, 6, 21964-21978.	0.8	19
349	Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Oncotarget, 2012, 3, 5-6.	0.8	26
350	Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget, 2015, 6, 27674-27687.	0.8	23
351	Genetic evaluation of BRCA1-A complex genes with triple-negative breast cancer susceptibility in Chinese women. Oncotarget, 2016, 7, 9759-9772.	0.8	3

#	ARTICLE	IF	CITATIONS
352	The RNA helicase A in malignant transformation. Oncotarget, 2016, 7, 28711-28723.	0.8	33
353	Germline <i>BRCA1</i> mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation―strategies in <i>BRCA1</i> carriers. Oncotarget, 2016, 7, 52974-52992.	0.8	26
354	Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. Oncotarget, 0, 7, 41285-41293.	0.8	47
355	Tissue specificity of DNA damage response and tumorigenesis. Cancer Biology and Medicine, 2019, 16, 396-414.	1.4	32
356	Evolving insights: how DNA repair pathways impact cancer evolution. Cancer Biology and Medicine, 2020, 17, 805-827.	1.4	17
357	DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics. Current Medicinal Chemistry, 2019, 26, 1483-1493.	1.2	15
358	When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development. Current Pharmaceutical Design, 2013, 19, 3263-3275.	0.9	24
359	Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis. International Journal of Molecular Sciences, 2020, 21, 870.	1.8	22
360	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. AIMS Medical Science, 2016, 3, 386-416.	0.2	3
361	Regulation of cancer stem cells by RING finger ubiquitin ligases. Stem Cell Investigation, 2014, 1, 5.	1.3	11
362	Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls. Cancer Research and Treatment, 2017, 49, 1012-1021.	1.3	28
363	BCR-ABL Hits at Mitosis; Implications for Chromosomal Instability, Aneuploidy and Therapeutic Strategy. , 0, , .		1
364	Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. Frontiers in Oncology, 2021, 11, 662055.	1.3	12
365	Genetic Differences between Physical Injury Patients With and Without Post-traumatic Syndrome: Focus on Secondary Findings and Potential Variants Revealed by Whole Exome Sequencing. Clinical Psychopharmacology and Neuroscience, 2021, 19, 683-694.	0.9	1
366	DNA Repair, Human Diseases and Aging. , 0, , .		0
367	DNA Damage Checkpoint Signaling Pathways in Human Cancer. , 2012, , 23-37.		0
368	Radiobiology as Applied to Radionuclide Therapy with an Emphasis on Low Dose Rate Radiation Effects. , 2013, , 383-407.		0
369	IONIZING RADIATION. , 2013, , 111-112.		0

#	ARTICLE	IF	Citations
370	Breast Cancer Invasion and Metastasis. , 2013, , 27-56.		1
371	DNA Double-Strand Break Repair in Tumorigenesis and Anticancer Treatment. Chemotherapy, 2014, 03, .	0.0	0
372	Prophylactic Oophorectomy for Patients with Germline BRCA Mutations. , 2017, , 65-87.		0
375	Emerging Perspectives on DNA Double-strand Breaks in Neurodegenerative Diseases. Current Neuropharmacology, 2019, 17, 1146-1157.	1.4	15
376	Heterogeneity of Circulating Tumor Cell–Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. Cancer Research, 2021, 81, 6196-6206.	0.4	5
377	Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes. Genome Medicine, 2021, 13, 174.	3.6	2
381	Human <i>BRCA</i> pathogenic variants were originated during recent human history. Life Science Alliance, 2022, 5, e202101263.	1.3	15
382	RNA Interference Induces <i>BRCA1</i> Gene Methylation and Increases the Radiosensitivity of Breast Cancer Cells. Cancer Biotherapy and Radiopharmaceuticals, 2022, , .	0.7	1
383	DNA binding and cleavage, BRCA1 gene interaction, antiglycation and anticancer studies of transition metal complexes of sulfonamides. Molecular Diversity, 2022, 26, 3093-3113.	2.1	1
384	BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling. Scientific Reports, 2022, 12, 4445.	1.6	2
385	Wwox Binding to the Murine Brca1-BRCT Domain Regulates Timing of Brip1 and CtIP Phospho-Protein Interactions with This Domain at DNA Double-Strand Breaks, and Repair Pathway Choice. International Journal of Molecular Sciences, 2022, 23, 3729.	1.8	2
386	Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair. Blood, 2022, 139, 3418-3429.	0.6	7
387	HspBP1 is a dual function regulatory protein that controls both DNA repair and apoptosis in breast cancer cells. Cell Death and Disease, 2022, 13, 309.	2.7	7
388	Spoken and Unspoken Matters Regarding the Use of Opioids in Cancer. Journal of Pain Research, 2022, Volume 15, 909-924.	0.8	0
389	Evaluation of conformational transitions of h-BRCA2 functional domain and unclassified variant Arg2502Cys using multimodal approach. International Journal of Biological Macromolecules, 2022, 209, 716-724.	3.6	2
390	Meiotic sex chromosome inactivation and the XY body: a phase separation hypothesis. Cellular and Molecular Life Sciences, 2022, 79, 18.	2.4	21
391	SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy. Cancer Genomics and Proteomics, 2022, 19, 328-338.	1.0	6
392	The Apoptotic Resistance of BRCA1-Deficient Ovarian Cancer Cells is Mediated by cAMP. Frontiers in Cell and Developmental Biology, 2022, 10, 889656.	1.8	8

#	Article	IF	CITATIONS
394	Relationship between B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) and homologous recombination regulatory genes in invasive ductal breast carcinomas. Histology and Histopathology, 2012, 27, 1353-9.	0.5	4
395	TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA. International Journal of Biological Sciences, 2022, 18, 2962-2979.	2.6	6
398	BRCA1-Dependent and Independent Recruitment of PALB2–BRCA2–RAD51 in the DNA Damage Response and Cancer. Cancer Research, 2022, 82, 3191-3197.	0.4	18
399	DNA Damage Response Regulation by Histone Ubiquitination. International Journal of Molecular Sciences, 2022, 23, 8187.	1.8	13
401	Phosphorylation of BRCA1 by ATM upon double-strand breaks impacts ATM function in end-resection: A potential feedback loop. IScience, 2022, 25, 104944.	1.9	6
402	UBE2T regulates epithelial–mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer. Journal of Ovarian Research, 2022, 15, .	1.3	3
403	BRCA1 and DNA damage response. Scientia Sinica Vitae, 2022, 52, 1763-1772.	0.1	1
404	Fumonisin B1 as a Tool to Explore Sphingolipid Roles in Arabidopsis Primary Root Development. International Journal of Molecular Sciences, 2022, 23, 12925.	1.8	1
406	BRCA1 mediates protein homeostasis through the ubiquitination of PERK and IRE1. IScience, 2022, 25, 105626.	1.9	4
407	Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma. Journal of Cancer Research and Therapeutics, 2022, 18, 1743.	0.3	0
408	BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy. Biomedicine and Pharmacotherapy, 2023, 158, 114090.	2.5	2
410	Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
411	Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy. , 2023, , 49-73.		0
424	Genetic Susceptibility to Prostate Cancer. , 2024, , 21-42.		0